Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression PR Newswire - Thu Apr 2, 7:00AM CDT

SALT LAKE CITY , April 2, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire - Tue Mar 10, 7:00AM CDT

SALT LAKE CITY , March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...

LPCN : 2.05 (-77.84%)
Lipocine: Q4 Earnings Snapshot AP - Tue Mar 10, 5:25AM CDT

Lipocine: Q4 Earnings Snapshot

LPCN : 2.05 (-77.84%)
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) PR Newswire - Wed Feb 18, 7:00AM CST

SALT LAKE CITY , Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Tue Jan 20, 7:00AM CST

SALT LAKE CITY , Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Mon Jan 12, 7:00AM CST

SALT LAKE CITY , Jan. 12, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Biotech’s New Edge: 5 Companies Mastering "How" We Dose BayStreet.ca - Fri Jan 2, 10:31AM CST

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. VANCOUVER – Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by 2034 as industry...

MOOD.CN : 0.5500 (unch)
WST : 254.80 (+0.82%)
PODD : 204.31 (-1.32%)
DOSEF : 0.6746 (+79.18%)
LPCN : 2.05 (-77.84%)
DARE : 1.7400 (-8.42%)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire - Tue Dec 16, 2025

SALT LAKE CITY , Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Tue Nov 18, 2025

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-77.84%)
Lipocine: Q3 Earnings Snapshot AP - Thu Nov 6, 2025

Lipocine: Q3 Earnings Snapshot

LPCN : 2.05 (-77.84%)

Barchart Exclusives

Hormuz Shutdown: Where are the Grain, Cattle, and Oil Markets Headed? Barchart - 58 minutes ago
The war in Iran is driving a historic surge in energy and grain prices while simultaneously threatening to break the cattle market due to rising input costs and shrinking consumer disposable income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.